ATE55247T1 - 13-cis-vitamin-a-saeure als wirksubstanz enthaltende arzneimittel. - Google Patents

13-cis-vitamin-a-saeure als wirksubstanz enthaltende arzneimittel.

Info

Publication number
ATE55247T1
ATE55247T1 AT85309084T AT85309084T ATE55247T1 AT E55247 T1 ATE55247 T1 AT E55247T1 AT 85309084 T AT85309084 T AT 85309084T AT 85309084 T AT85309084 T AT 85309084T AT E55247 T1 ATE55247 T1 AT E55247T1
Authority
AT
Austria
Prior art keywords
acid
active substance
pharmaceuticals containing
cis vitamin
cis
Prior art date
Application number
AT85309084T
Other languages
English (en)
Inventor
Paul J Jarosz
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Application granted granted Critical
Publication of ATE55247T1 publication Critical patent/ATE55247T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT85309084T 1984-12-14 1985-12-13 13-cis-vitamin-a-saeure als wirksubstanz enthaltende arzneimittel. ATE55247T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68197084A 1984-12-14 1984-12-14
EP85309084A EP0184942B1 (de) 1984-12-14 1985-12-13 13-Cis-Vitamin-A-Säure als Wirksubstanz enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
ATE55247T1 true ATE55247T1 (de) 1990-08-15

Family

ID=24737639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85309084T ATE55247T1 (de) 1984-12-14 1985-12-13 13-cis-vitamin-a-saeure als wirksubstanz enthaltende arzneimittel.

Country Status (9)

Country Link
EP (1) EP0184942B1 (de)
JP (1) JPS61145114A (de)
AT (1) ATE55247T1 (de)
AU (1) AU583568B2 (de)
CA (1) CA1282326C (de)
DE (1) DE3579128D1 (de)
DK (1) DK581185A (de)
GR (1) GR852997B (de)
PH (1) PH21591A (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5175002A (en) * 1991-10-02 1992-12-29 Du Pont Merck Pharmaceutical Company Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules
DE19603402A1 (de) * 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US6733779B2 (en) * 1999-08-26 2004-05-11 L. Dean Parks Method of treating benign prostatic hyperplasia and other benign prostate conditions
FR2807662A1 (fr) * 2000-04-12 2001-10-19 Cll Pharma Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications
IN192188B (de) * 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
AU2001289438A1 (en) * 2000-09-22 2002-04-02 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
US20050129773A1 (en) * 2001-12-06 2005-06-16 Inderdeep Bhatia Isotretinoin nanoparticulate compositions
EP1527774A1 (de) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG Neue Zubereitungsform für retinoidhaltige Weichgelatinekapseln
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010109259A1 (es) * 2009-03-26 2010-09-30 Grufarcol Ltda Métoda para preparar formulaciones de gel blando de isotretinoína líquida y la formulaciones obtenidas
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
SG2014011969A (en) 2009-05-20 2014-09-26 Ranbaxy Lab Ltd Liquid dosage forms of isotretinoin
MX2011012233A (es) 2009-05-20 2012-04-19 Ranbaxy Lab Ltd Soluciones de retinoide topicas.
JP5663025B2 (ja) 2009-09-15 2015-02-04 キューエルティー インコーポレイテッド 9−cis−レチニルエステルを脂質ビヒクル中に含む医薬製剤
EP2488022B1 (de) 2009-10-16 2018-01-10 Mochida Pharmaceutical Co., Ltd. Zusammensetzungen
RU2622763C2 (ru) 2010-04-19 2017-06-19 Новелион Терапьютикс Инк. Лечебная схема и способы лечения или уменьшения нарушений зрения, связанных с дефицитом эндогенных ретиноидов
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2013134867A1 (en) 2012-03-01 2013-09-19 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2019205030A1 (zh) * 2018-04-25 2019-10-31 人福普克药业(武汉)有限公司 盐酸金刚烷胺软胶囊及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124510A (en) * 1964-03-10 Stable dry powdered fat-soluble
ZA713539B (en) * 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
GB1590864A (en) * 1978-05-16 1981-06-10 Lilly Industries Ltd Thixotropic filling medium for hard gelatin capsules
US4322438A (en) * 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
JPH0244806B2 (ja) * 1981-09-07 1990-10-05 Sunstar Kk Bitaminaoanteinihaigoshitanyukakeihifugaiyozaisoseibutsu
CH658387A5 (de) * 1984-04-02 1986-11-14 Hoffmann La Roche Pharmazeutische praeparate.

Also Published As

Publication number Publication date
EP0184942A2 (de) 1986-06-18
DK581185D0 (da) 1985-12-13
DK581185A (da) 1986-06-15
AU583568B2 (en) 1989-05-04
AU5122685A (en) 1986-07-17
EP0184942B1 (de) 1990-08-08
GR852997B (de) 1986-04-16
CA1282326C (en) 1991-04-02
DE3579128D1 (de) 1990-09-13
EP0184942A3 (en) 1987-08-05
PH21591A (en) 1987-12-11
JPS61145114A (ja) 1986-07-02

Similar Documents

Publication Publication Date Title
ATE55247T1 (de) 13-cis-vitamin-a-saeure als wirksubstanz enthaltende arzneimittel.
DE69319440T2 (de) Herstellung von pharmazeutischen zusammensetzungen, die calcitonin enthalten
IL95691A0 (en) Thienylcarboxylates of amino alcohols,their preparation and pharmaceutical compositions containing them
KR870700620A (ko) 신규 약리학적 화합물
ATE64529T1 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
DE3669104D1 (de) Pharmazeutische praeparate, die ascorbinsaeurederivate enthalten.
AU532114B2 (en) Salts of n-substituted-2-pyrrolidone-4-carboxylic acids
NL192343B (nl) 17Ó-gesubstitueerde androsta-(1,)4-(di)een-3-on-17ß-carbonzuurverbindingen met een ontstekingswerende werkzaamheid en farmaceutische preparaten, die deze verbindingen bevatten.
IT1190824B (it) Composizione farmaceutica contenente 24,25-diidrossicolecalciferolo come ingrediente attivo
SE8404065D0 (sv) Novel biologically active compounds
DE3873232D1 (de) Ein dideoxynukleosid enthaltendes arzneimittel.
IL65922A0 (en) Preparation of apovincaminic acid esters,certain novel optically active derivatives thereof and pharmaceutical compositions containing them
ES8703459A1 (es) Procedimiento para la preparacion de derivados de acido 4- (isoxazolil)-tiazol-2-oxamico
DK99085D0 (da) Farmaceutiske praeparater indeholdende a-vitaminsyrederivater
NO862188L (no) Haarkondisjoneringspreparat som inneholder et amid av trialkyleddiksyre.
NL8100209A (nl) Methylpenamcarbonzuursulfonen, zouten en esters daarvan, alsmede geneeskundige preparaten, die deze verbindingen als actieve component bevatten.
NL193316B (nl) Onverzadigde cycloalifatische verbindingen, en cosmetische en farmaceutische preparaten, die deze onverzadigde cycloalifatische verbindingen bevatten.
DK192487D0 (da) Carbiovasculaere farmaceutiske praeparater, som er egnet til topisk indgivning
ES535408A0 (es) Un metodo de producir una composicion farmaceutica que contiene isoxicamato de l-arginina como ingrediente activo.
ATE56362T1 (de) Arzneimittel zur externen anwendung enthaltend aktives vitamin-d3.
ATE50494T1 (de) Pharmazeutische praeparate, die ascorbinsaeurederivate enthalten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee